Mouse Anti-LARGE1 Recombinant Antibody (LARGE-02) (CBMAB-L0694-YJ)

Name: Mouse Anti-LARGE1 Recombinant Antibody (LARGE-02)
SKU: CBMAB-L0694-YJ
Rating: 5 (1 reviews)

See all LARGE1 antibodies

Compare Online Inquiry

Datasheet

SDS

Request for COA

Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Host Animal

Mouse

Clone

LARGE-02

Application

Specificity

Human

Antibody Isotype

IgG2b

Clonality

Monoclonal

Application Notes

The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Buffer

PBS, pH 7.4

Storage

Store at 4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

More Infomation

Target

Full Name

LARGE xylosyl- and glucuronyltransferase 1

Introduction

LARGE1 is a member of the N-acetylglucosaminyltransferase gene family. LARGE1 may carry out the synthesis of glycoprotein and glycosphingolipid sugar chains. LARGE1 may also be involved in the addition of a repeated disaccharide unit. LARGE1 is the glycotransferase that adds the final xylose and glucuronic acid to alpha-dystroglycan and thereby allows alpha-dystroglycan to bind ligands including laminin 211 and neurexin. Mutations in this gene cause several forms of congenital muscular dystrophy characterized by cognitive disability and abnormal glycosylation of alpha-dystroglycan. Alternative splicing of this gene results in multiple transcript variants that encode the same protein.

Entrez Gene ID

9215

UniProt ID

O95461

Alternative Names

LARGE; MDC1D; MDDGA6; MDDGB6

Function

Bifunctional glycosyltransferase with both alpha-1,3-xylosyltransferase and beta-1,3-glucuronyltransferase activities involved in the maturation of alpha-dystroglycan (DAG1) by glycosylation leading to DAG1 binding to laminin G-like domain-containing extracellular proteins with high affinity (PubMed:22223806, PubMed:15752776, PubMed:15661757, PubMed:25279699, PubMed:25279697, PubMed:23125099, PubMed:21987822).
Elongates the glucuronyl-beta-1,4-xylose-beta disaccharide primer structure initiated by AC B4GAT1 by adding repeating units [-3-Xylose-alpha-1,3-GlcA-beta-1-] to produce a heteropolysaccharide (PubMed:22223806, PubMed:25279699, PubMed:25279697, PubMed:25138275, PubMed:32975514, PubMed:23125099).
Requires the phosphorylation of core M3 (O-mannosyl trisaccharide) by POMK to elongate the glucuronyl-beta-1,4-xylose-beta disaccharide primer (PubMed:21987822).
Plays a key role in skeletal muscle function and regeneration (By similarity).

Biological Process

Glycoprotein biosynthetic processManual Assertion Based On ExperimentTAS:UniProtKB
Glycosphingolipid biosynthetic processManual Assertion Based On ExperimentTAS:UniProtKB
Muscle cell cellular homeostasisISS:UniProtKB
N-acetylglucosamine metabolic processManual Assertion Based On ExperimentTAS:ProtInc
Protein glycosylationManual Assertion Based On ExperimentIMP:UniProtKB
Protein O-linked glycosylationTAS:Reactome
Protein O-linked mannosylationManual Assertion Based On ExperimentIDA:UniProtKB
Skeletal muscle organ developmentISS:UniProtKB
Skeletal muscle tissue regenerationISS:UniProtKB

Cellular Location

Golgi apparatus membrane

Involvement in disease

Muscular dystrophy-dystroglycanopathy congenital with impaired intellectual development B6 (MDDGB6):
A congenital muscular dystrophy associated with profound mental retardation, white matter changes and structural brain abnormalities. Skeletal muscle biopsies show reduced immunolabeling of alpha-dystroglycan.
Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A6 (MDDGA6):
An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound mental retardation, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

Topology

Cytoplasmic: 1-10
Helical: 11-31
Lumenal: 32-756

Okuma, H., Hord, J. M., Chandel, I., Venzke, D., Anderson, M. E., Walimbe, A. S., ... & Campbell, K. P. (2023). N-terminal domain on dystroglycan enables LARGE1 to extend matriglycan on α-dystroglycan and prevents muscular dystrophy. Elife, 12, e82811.

Katz, M., & Diskin, R. (2022). Structural basis for matriglycan synthesis by the LARGE1 dual glycosyltransferase. Plos one, 17(12), e0278713.

Joseph, S., Schnicker, N. J., Xu, Z., Yang, T., Hopkins, J., Watkins, M., ... & Campbell, K. P. (2022). Structure and mechanism of LARGE1 matriglycan polymerase. bioRxiv, 2022-05.

Yonekawa, T., Rauckhorst, A. J., El-Hattab, S., Cuellar, M. A., Venzke, D., Anderson, M. E., ... & Campbell, K. P. (2022). Large1 gene transfer in older myd mice with severe muscular dystrophy restores muscle function and greatly improves survival. Science advances, 8(21), eabn0379.

Inamori, K. I. (2022). Enzyme assay of protein-O-mannosyl glycan glycosyltransferases (LARGE1/2). Glycoscience Protocols (GlycoPODv2)[Internet].

Liu, Y., Huang, S., Kuang, M., Wang, H., & Xie, Q. (2021). High LARGE1 expression may predict benefit from adjuvant chemotherapy in resected non-small-cell lung cancer. Pharmacogenomics and Personalized Medicine, 87-99.

Lyu, J., Wang, D., Duan, P., Liu, Y., Huang, K., Zeng, D., ... & Li, Y. (2020). Control of grain size and weight by the GSK2-LARGE1/OML4 pathway in rice. The Plant Cell, 32(6), 1905-1918.

Walimbe, A. S., Okuma, H., Joseph, S., Yang, T., Yonekawa, T., Hord, J. M., ... & Campbell, K. P. (2020). POMK regulates dystroglycan function via LARGE1-mediated elongation of matriglycan. Elife, 9, e61388.

Righino, B., Bozzi, M., Pirolli, D., Sciandra, F., Bigotti, M. G., Brancaccio, A., & De Rosa, M. C. (2020). Identification and modeling of a GT-A fold in the α-dystroglycan glycosylating enzyme LARGE1. Journal of Chemical Information and Modeling, 60(6), 3145-3156.

Beltrán, D., Anderson, M. E., Bharathy, N., Settelmeyer, T. P., Svalina, M. N., Bajwa, Z., ... & Campbell, K. P. (2019). Exogenous expression of the glycosyltransferase LARGE1 restores α-dystroglycan matriglycan and laminin binding in rhabdomyosarcoma. Skeletal Muscle, 9, 1-10.

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Have you used Mouse Anti-LARGE1 Recombinant Antibody (LARGE-02)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Request bulk or custom quote Second antibody and isotype control

Contact us

Tel: (USA)
(UK)
Fax:

Global Locations

Email:

Online Inquiry